# Ecolab Inc. (ECL) — InvestMoat Analysis

_Last analyzed: September 17, 2026_
_Asset class: equity · Canonical page: https://investmoat.com/stocks/ecl_

## Scores

| Dimension | Score (0–100) |
| --- | --- |
| Moat durability | 71 |
| Growth trajectory | 72 |
| Valuation | 72 |
| **Composite** | **72** |

Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes.

## Key stats

- **Ticker:** ECL
- **Market Cap:** ~$77B

## Moat

Ecolab's moat is switching-cost embedding: chemistry, dispensers, and field service wired into customer water, hygiene, and infection-prevention workflows, topped by a One Ecolab multi-platform bundle. Competitors can sell a drum of chemicals; replacing the installed program, compliance trail, and service relationship is operationally painful.

### The Consumables + Service Embedding Moat

ECL runs a **Mission-Critical Consumables Toll** that compounds through on-site embedding, program switching costs, and platform breadth:

- **Installed Chemistry and Dispenser Lock-In:** Ecolab sells programs, not spot chemicals: dosing equipment, service routes, and formulated products sit inside plant water loops, commercial kitchens, laundry, and healthcare protocols. Ripping them out means requalifying chemistry, retraining staff, and accepting process risk — classic transaction embedding. Q2 volume still grew (+1% reported; nearly −1 pt Middle East disruption) while pricing improved to ~4%, evidence the franchise can pass through cost without a volume collapse.
- **One Ecolab Cross-Platform Bundle:** Global Water (~half of sales), Institutional & Specialty, Pest Elimination, and Life Sciences share a field force and account relationship. Share gains in Food & Beverage, Institutional, and Light Water in Q2 were explicitly framed as One Ecolab wins — bundling raises the cost of cherry-picking a single category competitor.
- **Digital Monitoring Layer (Open Depth):** Ecolab Digital sales rose 27% to $121M in Q2 on hardware subscriptions and software. Telemetry and compliance records deepen stickiness, but this thin first pass does not underwrite NRR, attach rates, or AI-agent durability of the digital stack — flagged for restamp rather than credited as a second fortress.
- **Growth Engines Extend the Same Moat:** Global High-Tech (+29% organic) and Life Sciences (+15% organic) apply the same water/chemistry/service model to microelectronics, data-center liquid cooling (CoolIT), and bioprocessing. CoolIT extends embedding into AI infrastructure water loops; Ovivo Electronics adds ultrapure-water adjacency. Moat type is still embedding — the end markets are new.

**Moat verdict:** ECL's moat is AI-resilient operational embedding: consumables + equipment + service inside customer water, hygiene, and infection-prevention workflows. Software can assist dosing; it does not painlessly relocate an installed program. Digital and High-Tech are additive but not yet fully underwritten fortresses on this thin first pass.

## Growth

Q2 2026 (reported Jul 28, 2026; quarter ended Jun 30) printed sales $4.415B (+10% reported, +5% organic), adjusted operating income $809M (+10%), and adjusted diluted EPS $2.09 (+11%). Pricing improved to ~4% (energy surcharge ramp); reported volume +1% despite a nearly 1 pt Middle East disruption headwind. Segment organic sales: Global Water +4% (High-Tech +29%), Institutional & Specialty +4%, Pest Elimination +7%, Life Sciences +15%. Organic OI margin 18.8% (+40 bps). Management raised FY2026 adjusted EPS to $8.05–$8.25 (+7% to +10%) and guided H2 organic sales to 6–7% with pricing 5–6%; long-term organic sales algorithm 5–7% with OI margins expanding beyond 20%. Global High-Tech annualized sales approaching ~$1.5B with a stated path to $4B by 2030.

- **Revenue CAGR estimate:** 7-10%
- **Primary type:** both
- **Margin trend:** expanding
- **Key risk (moderate):** If organic sales stall back below ~4% for two consecutive quarters — because pricing power fades against commodities, CoolIT/High-Tech integration disappoints, or Heavy Water/Paper re-widens as a drag — the 7–10% EPS CAGR band has to be rewritten lower and the margin-to-20% path slips.
- **Drivers:**
  - Organic sales + pricing — Q2 organic +5% (pricing ~4%, volume +1% w/ ME headwind); H2 organic guided 6–7% with pricing 5–6% (accelerating)
  - Growth engines (High-Tech + Life Sciences) — High-Tech +29% organic; Life Sciences +15% organic; High-Tech annualized ~$1.5B with CoolIT / Ovivo adjacency (accelerating)
  - Institutional & Specialty core — Organic sales +4%; OI margin 24.1% (+50 bps); hospitality / QSR share gains vs soft end markets (stable)
- **Score derivation:** Base 70.7 (7–10% EPS CAGR midpoint 8.5%) + 2.7 trajectory (organic sales and growth engines accelerating; Institutional & Specialty stable) + 4 expanding margins − 5 moderate risk (commodities / CoolIT integration / cyclical Heavy Water-Paper) = 72

## Valuation

At $274.79 (Yahoo Sep 17, 2026 live), ECL screens about 31% above the $210 bear and about 8% below the $300 base. On the raised FY2026 adj. EPS midpoint (~$8.15) the stock is ~33.7× 2026E earnings — a quality-compounder multiple that is fair if 5–7% organic and margin expansion hold, rich if growth reverts to low-single digits. Thin first pass — ladder is EPS-multiple anchored, not a full DCF/FCF build.

**Fair value:** $300 — Base fair value $300 assumes organic sales sustain mid/high-single digits into 2027, OI margins progress toward 20%+, and the market pays ~33–34× on ~$9 look-through adj. EPS. Live tape $274.79 (Sep 17); ~$77B equity value on ~280M shares. Not a hire screen — coverage valuation only.

| Multiple | Value | Note |
| --- | --- | --- |
| Price / 2026E Adj. EPS | ~33.7× | $274.79 ÷ ~$8.15 midpoint of $8.05–$8.25 guide |
| Forward P/E (Street NTM, rough) | ~34–35× | Yahoo-style forward context; quality industrial compounder band |
| Price / Sales (TTM, rough) | ~4.6× | ~$77B equity / ~$16.8B TTM sales — secondary to P/E for this franchise |
| Organic OI margin (Q2) | 18.8% | +40 bps YoY; mgmt path beyond 20% OI margin (2027 framing) |
| Balance-sheet snapshot (Jun 30) | Cash $5.1B / LT debt $11.9B | Elevated cash and debt after acquisition financing (Ovivo / CoolIT); FCF conversion open for restamp |

ECL is priced as a durable mid/high-single-digit compounder, not as a distressed chemical name and not as a hypergrowth software proxy. If H2 organic lands in the 6–7% guide and High-Tech keeps double-digit momentum, ~34× 2026E leaves modest upside toward the $300 base. If organic fades and CoolIT amortization/financing costs linger without growth proof, the multiple can compress toward the $210 bear without a balance-sheet accident. Digital attach and FCF conversion remain the largest unmodeled swings on this thin pass. _(as of September 17, 2026)_

## Price scenarios

### Bear — $210

Organic growth stalls, CoolIT integration disappoints, and the quality multiple compresses toward ~26× on flattish EPS.

- Organic sales fall back below ~3–4% for two+ quarters as pricing power fades against sustained commodity inflation
- Global High-Tech / CoolIT fails to sustain double-digit growth; liquid-cooling competition or integration costs erase the growth-engine narrative
- Heavy Water and Paper headwinds re-widen; Institutional comps soften with hospitality/QSR traffic
- Multiple compresses to ~26× on ~$8 EPS → ~$210; still a franchise, but de-rated from compounder premium

### Base — $300

5–7% organic holds, margins grind toward 20%+, and High-Tech scales — market pays ~33–34× on look-through earnings.

- FY2026 adj. EPS lands inside $8.05–$8.25; 2027 EPS grows high-single digits as CoolIT dilution fades and pricing stays mid-single digit
- H2 2026 organic prints in the guided 6–7% range; consolidated organic holds mid-single digits into 2027
- Organic OI margin progresses toward ~20%; Institutional & Specialty margins stay mid-20s
- ~33–34× on ~$9 look-through adj. EPS supports ~$300; buybacks continue at a moderate pace

### Bull — $380

High-Tech and Life Sciences become durable double-digit engines, margins clear 20% early, and the multiple expands on accelerating EPS.

- Global High-Tech outperforms on data-center liquid cooling and microelectronics ultrapure water; credible progress toward the $4B / 25% OI-margin 2030 framing
- Life Sciences sustains mid-teens organic with bioprocessing share gains; Pest stays high-single-digit
- OI margins clear 20% ahead of the 2027 framing while organic sales hold high-single digits
- Market restores ~36–38× on growing earnings → ~$380

---

InvestMoat is a research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.